Skip to main content

Advertisement

Table 5 Characteristics and medical costs of patients in the persistent group

From: Persistence rates and medical costs of biological therapies for psoriasis treatment in Japan: a real-world data study using a claims database

  Total BT-naïve
ADL IFX UST Sub total ADL IFX UST Sub total
Number of patients 6 6 29 42 4 6 23 33
Average Age 50.8 44.7 45.0 46.0 54.0 44.7 44.8 45.9
%Female 16.7% 16.7% 17.2% 16.7% 25.0% 16.7% 21.7% 21.2%
Cost (pre) ¥1092 ¥1062 ¥925 ¥988 ¥360 ¥1062 ¥597 ¥653
In 1000 JPY unit IP ¥55 ¥603 ¥315 ¥340 ¥0 ¥603 ¥201 ¥250
OP ¥876 ¥398 ¥418 ¥473 ¥263 ¥398 ¥211 ¥251
RX ¥161 ¥61 ¥192 ¥175 ¥97 ¥61 ¥186 ¥152
Cost increase ¥1606 ¥2246 ¥1875 ¥1883 ¥2433 ¥2246 ¥2211 ¥2244
In 1000 JPY unit IP - ¥55 - ¥174 - ¥147 - ¥140 ¥0 - ¥174 - ¥98 - ¥100
OP ¥1365 ¥2446 ¥2114 ¥2054 ¥2461 ¥2446 ¥2380 ¥2402
RX ¥295 - ¥26 - ¥91 - ¥30 - ¥27 - ¥26 - ¥71 - ¥57
  1. ADL Adalimumab, IFX Infliximab, UST Ustekinumab, pre:12 months pre-initiation, cost increase: increase from pre to post 12 months post-initiation, JPY Japanese Yen, IP inpatient medical costs, OP outpatient medical cost, RX costs of drugs other than BTs